Objective. To investigate the efficacy of surgery in the treatment of metastatic renal cell carcinoma (mRCC) and to identify prognostic factors. Methods. A single center retrospective study of 96 patients with mRCC from December 2004 to August 2013.
Results. The median follow-up time was 45 months. Thirty-one (32. 3%) of the patients received complete resection of metastatic sites, 11 (11. 5%) of the patients underwent incomplete resection of metastatic sites, and 54 (56. 3%) of the patients received no surgery. In the univariate Kaplan-Meier analysis, the median overall survival times of the three groups were 52 months, 16 months, and 22 months, respectively (p < 0. 001). The difference in the overall survival time was statistically significant between complete resection and no surgery groups (HR = 0. 43, p = 0. 009), while there was no significant difference between the incomplete metastasectomy and no surgery groups (HR = 1. 80, p = 0. 102). According to the multivariate Cox regression analysis, complete metastasectomy (HR = 0. 49, p = 0. 033), T stage > 3 (HR = 1. 88, p = 0. 015), disease free interval 3, disease free interval
BioMed research international. 2015 Oct 11 [Epub]
Xiaoteng Yu, Bing Wang, Xuesong Li, Gang Lin, Cuijian Zhang, Yang Yang, Dong Fang, Yi Song, Zhisong He, Liqun Zhou
Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Orthopedics, Peking University First Hospital, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Thoracic Surgery, Peking University First Hospital, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China. , Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China.